Study on daptomycin use and implementation of an antimicrobial stewardship program
- 436 Downloads
Background Treatment of Gram-positive pathogens remains a major health issue due to the presence of methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant Enterococcus spp. Daptomycin offers an alternative after therapeutic failure using glycopeptides. Yet its use requires strict control given its financial impact and environmental risks. Since 2014, the use of daptomycin within our hospital has intensified, occasionally outside the scope of its approved indications. Objectives: The aim of this study is to analyze the appropriateness of daptomycin prescriptions. Setting This work was conducted in a 1500-bed University Hospital. Method A descriptive retrospective study was conducted from November 2013 to July 2014. All patients having received at least 2 days of treatment were included. Analysis of the appropriateness of daptomycin prescriptions was conducted by a multidisciplinary team comprised of infectious diseases specialists, pharmacists and a microbiologist. The appropriateness of daptomycin prescriptions was established based on Infectious Diseases Society of America recommendations published in 2011. Main outcome measures: The indicators chosen to determine appropriateness of prescription were: treatment indication, prescribed dose and other antibiotics associated with the daptomycin prescription. Results 19 patients (14 men/5 women) were included. Observed indications were: bone and joint infection (n = 6; 32 %), infectious endocarditis (n = 5; 26 %), bacteremia (n = 5; 26 %) and complicated skin and soft tissue infection (n = 3; 16 %). Identified pathogens were: MRSA (n = 14; 74 %), methicillin-resistant coagulase-negative Staphylococcus (n = 4; 21 %) and Streptococcus mitis (n = 1; 5 %). Daptomycin was prescribed as first-line treatment in 32 % of cases (n = 6). The mean dosage was 9 mg/kg/day (5–11 mg/kg/day) for a mean duration of 11 days (2; 55 days). Clinical success was observed in 42 % of cases (n = 8). Appropriateness for daptomycin use was only established for 15 % of prescriptions (n = 3). Conclusion Faced with a lack of recent recommendations on the subject, our multidisciplinary team issued a local consensus, defining the indications and dosage modalities for this reserve antibiotic. This multidisciplinary approach enables improved use of recent anti-MRSA drugs
KeywordsAntimicrobial stewardship Bone and joint infection Daptomycin Endocarditis France Prescribing audit
The authors thank the following pharmacists for their contribution to data collection: Morgane Bonnet, Angélique Cotteau-Leroy, Marie-Christine Douet, Thierry Henon, Dominique Levêque, Isabelle Poujol and Isabelle Tiret.
The authors received no funding for this study.
Conflicts of interest
The authors declare they have no conflict of interest concerning this article
- 3.French National Agency for Drug and Health Safety (France). Transparency Committee: daptomycin. Haute Autorité de santé; 2006 Oct. France. http://www.hassante.fr/portail/upload/docs/application/pdf/2009-01/ct_2927_cubicine_ang_2009-01-15_11-30-23_417.pdf. Accessed Feb 2014
- 15.Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. Clin Infect Dis. 2013;56(11):1562–9.CrossRefPubMedGoogle Scholar
- 17.French National Agency for Drug and Health Safety (France). Clinical Practice Guidelines: Antibiotic therapy and prevention of bacterial resistance in healthcare organization. Haute Autorité de Santé; 2008 Apr. France. http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-03/antibiotic_therapy_and_prevention_of_bacterial_resistance_guidelines.pdf. Accessed March 2014
- 18.Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):285–92.CrossRefPubMedGoogle Scholar
- 19.French National Agency for Drug and Health Safety (France). Caractérisation des antibiotiques considérés comme « critiques». ANSM. 2013 Nov. France. http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Les-antibiotiques-consideres-comme-critiques-premieres-reflexions-sur-leur-caracterisation-Point-d-information. Accessed March 2014
- 24.Byren I, Rege S, Campanaro E, Yankelev S, Anastasiou D, Kuropatkin G, et al. Randomized controlled trial ofthe safety and efficacy of daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother. 2012;56(11):5626–32.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–77.CrossRefPubMedGoogle Scholar